Summary & Overview
HCPCS Level II J0257: Alpha-1 Proteinase Inhibitor (Glassia), 10 mg
HCPCS Level II code J0257 identifies the injectable human alpha-1 proteinase inhibitor product Glassia, billed per 10 mg unit. This biologic replacement therapy is used for augmentation in patients with alpha-1 antitrypsin deficiency and is typically administered in hospital outpatient departments, infusion centers, or physician offices. The code matters nationally because biologic therapies for rare conditions drive specialty drug spending, influence site-of-care decisions, and require specific coverage and medical necessity documentation.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coding context, typical sites of service, and common billing considerations for administration of J0257. The publication summarizes benchmark elements relevant to specialty drug billing—unitization, infusion-related service lines, and payer coverage patterns—and highlights areas where policy updates or payer edits commonly affect reimbursement and prior authorization requirements.
The report also provides clinical context for use of alpha-1 proteinase inhibitor replacement, operational implications for infusion delivery, and a clear list of what is and is not available from the input data. Data not available in the input includes specific associated taxonomies, ICD-10 diagnoses, related codes, and service-line details beyond the described product.
Billing Code Overview
HCPCS Level II code J0257 describes an injectable alpha-1 proteinase inhibitor (human), brand Glassia, dosed per 10 mg unit. This code represents the drug product used for replacement therapy in patients with alpha-1 antitrypsin deficiency requiring augmentation of serum levels.
Service type: Pharmaceutical injection / biologic replacement therapy
Typical site of service: Hospital outpatient department, infusion center, or physician office
Clinical & Coding Specifications
Clinical Context
A 48-year-old male with severe alpha-1 antitrypsin deficiency attends the infusion clinic for a scheduled intravenous dose of alpha-1 proteinase inhibitor (human) therapy, provided as J0257 (Glassia) dosed per provider order. The patient presents with a prior authorization and documented baseline spirometry, oxygen saturation, and weight to calculate dose. The clinical workflow includes pre-infusion nursing assessment (vital signs, allergy check, IV access verification), verification of product lot and expiration, administration of the J0257 infusion over the prescribed infusion time with continuous monitoring for infusion reactions, and post-infusion observation and documentation. Billing includes the HCPCS code J0257 reported per 10 mg unit administered, possible administration or infusion codes as applicable, and applicable modifiers to indicate circumstances (e.g., patient condition, service distinctiveness, or drug wastage). Typical sites of service are outpatient infusion centers, hospital outpatient departments, and occasionally skilled nursing or long-term care facilities when medically appropriate. Typical patient scenario: chronic weekly or biweekly replacement therapy for emphysema related to alpha-1 antitrypsin deficiency with routine monitoring of pulmonary function and liver status.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|